Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a Waltham, Massachusetts-based biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. News about Viridian often centers on its late-stage programs in thyroid eye disease (TED), regulatory milestones, clinical trial updates, and financing activities that support its pipeline and anticipated commercialization efforts.
Investors following VRDN news can expect frequent updates on veligrotug, Viridian’s intravenously delivered anti–IGF‑1R antibody for TED. Company announcements have highlighted the completion of two global phase 3 trials, THRIVE and THRIVE‑2, positive topline data, and the U.S. Food and Drug Administration’s acceptance of a Biologics License Application with Priority Review and a defined PDUFA target action date. News releases also discuss preparations for a potential commercial launch, including market access, medical affairs, and engagement with a core prescriber base.
Another key news theme is VRDN‑003 (elegrobart), a subcutaneous, half‑life extended anti‑IGF‑1R antibody in phase 3 trials REVEAL‑1 and REVEAL‑2 for active and chronic TED. Viridian’s press releases describe enrollment progress, anticipated topline data timing, and the design of VRDN‑003 for subcutaneous administration in a low‑volume autoinjector with every‑four‑week or every‑eight‑week dosing. Updates on Viridian’s FcRn inhibitor portfolio—including VRDN‑006 and VRDN‑008—cover proof‑of‑concept IgG reduction data, investigational new drug (IND) submissions, and preclinical head‑to‑head findings.
VRDN news also frequently includes corporate and financial developments, such as public equity offerings, royalty financing agreements, amended credit facilities, and collaboration and license agreements like the partnership with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. These disclosures provide context on how Viridian plans to fund its clinical programs and potential commercial launches. For a comprehensive view of Viridian’s evolving TED pipeline, autoimmune disease programs, and capital strategy, readers can review the ongoing stream of press releases, earnings updates, and SEC-reported events associated with the VRDN ticker.
Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., its President and CEO, will present a company overview at the Oppenheimer Rare & Orphan Disease Summit on May 21 at 9:05 a.m. ET. He will also participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1 at 11:30 a.m. ET. Both events will be accessible via webcasts on Viridian's website, with replays available for 90 days post-event. Viridian focuses on developing treatments for serious diseases, notably its anti-IGF-1R monoclonal antibody, VRDN-001, targeting Thyroid Eye Disease.
Viridian Therapeutics reported significant milestones in its thyroid eye disease (TED) programs VRDN-001 and VRDN-002. Both candidates are on track for IND filings in Q4 2021, with VRDN-001 showing promising preclinical data. As of March 31, 2021, the company had $117 million in cash, sufficient to fund operations into 2024. R&D expenses rose to $13.8 million due to advancing lead programs, while net losses increased to $18.5 million compared to last year.
Viridian Therapeutics (NASDAQ: VRDN) announced its financial results for Q4 and 2020, highlighting a significant cash position of $127.6 million, sufficient to fund operations into 2023. The company's revenue declined to $1.1 million for the year, primarily due to reduced activities related to legacy assets. Key developments include the advancement of lead programs VRDN-001 and VRDN-002, with IND filings expected by the end of 2021. Following the October 2020 merger, Viridian appointed a new leadership team, aiming to expand its pipeline and R&D for Thyroid Eye Disease (TED).
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced a conference call and webcast on March 25, 2021, at 4:30 p.m. ET. The call will cover a corporate update and the results for Q4 and the full year 2020. Interested participants can join by calling 877-407-0789 domestically or 201-689-8562 internationally, using Conference ID 13717079. The live webcast is accessible via their Investor Relations website.
Viridian focuses on developing treatments for serious diseases, notably VRDN-001, an anti-IGF-1R monoclonal antibody for thyroid eye disease.
Viridian Therapeutics (NASDAQ: VRDN), a biopharmaceutical company, announced that CEO Jonathan Violin will present at several upcoming investor conferences. Key events include the SVB Leerink 10th Annual Global Healthcare Conference on February 24, the Cowen 41st Annual Health Care Conference on March 3, and the Oppenheimer 31st Annual Healthcare Conference on March 16. Each presentation will be available for online viewing, with replays archived for 90 days. The company's lead program, VRDN-001, targets thyroid eye disease.
Viridian Therapeutics, formerly miRagen Therapeutics, has appointed Jonathan Violin, Ph.D., as President and CEO, succeeding Lee Rauch, who remains a strategic advisor. Barrett Katz, M.D., has joined as Chief Medical Officer. The company is developing VRDN-001 and VRDN-002 for thyroid eye disease, targeting a significant unmet medical need. Recent licensing from Xencor allows for the development of therapeutic antibodies. Viridian aims to file Investigational New Drug applications for both products in 2021.